m+Medelevator.RU
← Поиск публикаций
Journal of gastrointestinal cancer · 2026

Characterization of Lymphocyte Subsets in Peripheral Blood of Patients with Colorectal Cancer.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Wu Guanghai, Zheng Kunming, Han Wang, Xu Shichao, Xu Jing

Аннотация

PURPOSE: Cellular immune response to cancer is known to be of great importance for tumor control. Until now, the role of systemic immune profiles in tumor progression remains unclear. METHODS: By using multiparameter flow cytometry, the subset distribution and immunophenotype of lymphocyte subsets were investigated in peripheral blood mononuclear cell samples from 117 colorectal cancer (CRC) patients and 77 healthy donors. RESULTS: Compared with the normal group, the numbers of T lymphocytes and Th lymphocytes were significantly decreased in the CRC group, whereas the number of NK cells was significantly increased. There was no significance between the two groups in the numbers of Ts, γδT, and CD4 + /CD8 + lymphocytes. The number of T lymphocytes was significantly increased after surgical resection, however, the number of B lymphocytes was significantly decreased. There was no significance in the number of other lymphocyte subsets neither before nor after rection. The number of NK cells increased in stage III-IV, as compared to stage I-II. The numbers of Ts and CD4 + /CD8 + lymphocytes showed a correlation with the tumor differentiation degree. The number of T lymphocytes was higher in conditions that were without lymph node invasion and distant metastasis. The number of CD4 + /CD8 + lymphocytes was significantly higher in the condition without perineural invasion. CONCLUSION: The altered phenotype of circulating immune cell subsets in CRC and its association with clinical outcome may facilitate the development of new therapeutics against CRC, and thereby contributing to better insight into the role of systemic immune profiles in tumor progression.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты